|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-2-28
|
|
pubmed:abstractText |
Renal cell carcinoma (RCC) is considered a cytokine-responsive tumor. The clinical course of a patient may thus be influenced by the patient's capacity to produce distinct cytokines. Therefore, cytokine gene polymorphisms in RCC patients were analyzed to determine haplotype combinations with prognostic significance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
845-51
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:17327605-Carcinoma, Renal Cell,
pubmed-meshheading:17327605-Female,
pubmed-meshheading:17327605-Haplotypes,
pubmed-meshheading:17327605-Humans,
pubmed-meshheading:17327605-Interleukin-10,
pubmed-meshheading:17327605-Interleukin-4,
pubmed-meshheading:17327605-Kidney Neoplasms,
pubmed-meshheading:17327605-Linkage Disequilibrium,
pubmed-meshheading:17327605-Male,
pubmed-meshheading:17327605-Middle Aged,
pubmed-meshheading:17327605-Multivariate Analysis,
pubmed-meshheading:17327605-Polymorphism, Genetic,
pubmed-meshheading:17327605-Promoter Regions, Genetic,
pubmed-meshheading:17327605-Transforming Growth Factor beta1
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Central Institute for Blood Transfusion and Immunological Department, Innsbruck Medical University, Innsbruck, Austria.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
